Efficacy and Tolerability of Eight Antimicrobial Regimens in the Outpatient Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease
DOI:
https://doi.org/10.3889/oamjms.2014.093Keywords:
adverse effect, antibiotic, chronic obstructive pulmonary disease, clinical success, exacerbation.Abstract
BACKGROUND: Bacterial infections are considered as the most important cause of exacerbations in patients with chronic obstructive pulmonary disease.
AIM: To compare the efficacy and tolerability of eight antibiotics empirically administered for outpatient treatment of exacerbations of COPD.
METHODS: We performed an observational study including 343 COPD patients with probable bacterial exacerbation (Group A and Group B COPD patients) managed in an outpatient setting. Eight antibiotic regimens each used 10 days were evaluated: amoxicillin/clavulonic acid, doxycycline, cefuroxime, cefixime, clarithromycin, roxithromycin, ciprofloxacin, and moxifloxacin. All patients were followed up for 30 days, with an intermediate visits at 5, 7 and 10 days at which the duration of symptoms and the side-effects of the drug were evaluated.
RESULTS: The clinical success rate varied from 69.8% with doxycycline to 80.9% with moxifloxacin. The mean time to relief of symptoms varied from 5.6 days with moxifloxacin to 6.3 days with amoxicillin/clavulonic acid. Significant increase of the post-treatment FEV1value was registered in all treatment groups. Relapse within the first 20 days was registered in the group receiving doxycycline, clarithromycin, and ciprofloxacin. The prevalence of the adverse events was low varying from 6.7% with cefuroxime to 11.3% with ciprofloxacin.
CONCLUSION: Our findings suggest high clinical success rate and high safety of all studied regimens.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2011 Update. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf (30.10.2012).
Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000; 55: 114-120. DOI: https://doi.org/10.1136/thorax.55.2.114
Miravittles M, Niederman M. Lectures in Respiratory Tract Infections: Acute Exacerbations of Chronic Bronchitis. London: Science Press Ltd, 2004: p. 7-8.
Ball P, Chodosh S, Grossman R, Tillotson G, Wilson R. Causes, epidemiology, and treatment of bronchial infections. Infect Med. 2000; 17: 186-198.
Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002; 347: 465-471. DOI: https://doi.org/10.1056/NEJMoa012561
Sethi S, Wrona C, Grant BJB, Murphy TF. Strain specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 169: 448-453. DOI: https://doi.org/10.1164/rccm.200308-1181OC
Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med. 2002; 9: 191-197. DOI: https://doi.org/10.1097/00045413-200207000-00001
Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995; 108: 43S-52S. DOI: https://doi.org/10.1378/chest.108.2_Supplement.43S
Anthonisen NR, Menfreda J, Warren CP, Herschfield EG, Harding HK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106 (2): 196-204. DOI: https://doi.org/10.7326/0003-4819-106-2-196
Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJM. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005; 26: 1138-1180. DOI: https://doi.org/10.1183/09031936.05.00055705
Celli BR, MacNee W. Satandards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23 (6): 932-946. DOI: https://doi.org/10.1183/09031936.04.00014304
Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Bruce M, Lomas DA, Agusti A, MacNeeW, Calverley P, Rennard S, Wouters EFM, Wedzicha JA for the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363: 1128-1138. DOI: https://doi.org/10.1056/NEJMoa0909883
Miravittles M, Llor C, Naberan K, Cots JM, Molina J. Effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin Drug Invest. 2004; 24 (2): 63-72. DOI: https://doi.org/10.2165/00044011-200424020-00001
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2010 Update. Available at: http://www.goldcopd.org/Guidelines/guideline-2010-gold-report.html (30.10.2012).
Andersson F, Borg S, Jansson S-A, Jonsson AC, Ericsson A, Prütz C, Rönmark E, Lundbäck B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002; 96: 700-708. DOI: https://doi.org/10.1053/rmed.2002.1334
Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007; 29: 1224-1238. DOI: https://doi.org/10.1183/09031936.00109906
Balter MS, La Forge J, Low D, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003; 10: 3B-32B. DOI: https://doi.org/10.1155/2003/486285
Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000; 117: 1638-1645. DOI: https://doi.org/10.1378/chest.117.6.1638
Minov J, Karadzinska-Bislimovska J, Vasilevska K, Stoleski S. Smoking status in exposed and unexposed workers. Mak Med Pregled. 2006;60 (68):128.
Minov J, Karadzinska-Bislimovska J, Vasilevska K, Risteska-Kuc S, Stoleski S. Exposure to environmental tobacco smoke in the workplace in Macedonia: Where are we now? Arh Hig Rada Toksikol. 2008; 59: 103-109. DOI: https://doi.org/10.2478/10004-1254-59-2008-1870
Pérez-Trallero E, Fernández-Mazarrasa C, GarcÃa-Rey C, Bouza E, Aguilar L, GarcÃa-de-Lomas J, Baquero F; Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain; Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemoter. 2001; 45: 3334-3340. DOI: https://doi.org/10.1128/AAC.45.12.3334-3340.2001
Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of the antimicrobial resistance among respiratory tract isolates of in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Inf Dis. 1998; 27: 764-770. DOI: https://doi.org/10.1086/514953
Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2001; 134: 595-599. DOI: https://doi.org/10.7326/0003-4819-134-7-200104030-00015
Garcia JA, Baquero F, Garcia de Lomas J, Aquilar L. Antimicrobial susceptibility of 1,422 Haemophilus influenzae isolates from respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study in Spain; Spanish Surveillance Group for Respiratory Pathogens. Infection. 1999; 27: 265-267. DOI: https://doi.org/10.1007/s150100050026
Hunter MH, King DE. COPD: Management of acute exacerbations and chronic stable disease. Am Fam Physician. 2001; 64 (4): 603-613.
Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens - a global perspective. Semin Respir Infect. 2000; 15: 195-207. DOI: https://doi.org/10.1053/srin.2000.18066
Minov J, Karadzinska-Bislimovska J, Petrova T, Vasilevska K, Risteska-Kuc S, Stoleski S, Mijakoski D. Efficacy and tolerability of various antimicrobial regimens in the treatment of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in outpatients. Maced J Med Sci. 2009; 2(2): 115-120. DOI: https://doi.org/10.3889/MJMS.1857-5773.2009.0040
Wilson R, Allegra L, Huchon G, Izquierdo JL, Jones P, Schaberg T, Sagnier PP; MOSAIC Study Group. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic therapy for the treatment of acute exacerbations of chronic bronchitis. Chest. 2004; 125: 953-964. DOI: https://doi.org/10.1378/chest.125.3.953
Miravitlles M, Zalacain R, Murio C, Ferrer M, Alvarez-Sala JL, Masa JF, Verea H, Ros F, Vidal R; on behalf of the IMPAC Study Group. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: a results of a two-years study. IMPAC Study Group. Clin Drug Invest. 2003; 23: 439-450. DOI: https://doi.org/10.2165/00044011-200323070-00003
Wilson R, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Sethi S. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J. 2012;40(1):17-27. DOI: https://doi.org/10.1183/09031936.00090311
Siempos II, Dimopoulos G, Korbila JP, Manta K, Falagas ME. Macrolides, quinolones and amoxicillin/clavulonate for chronic bronchitis: meta-analysis. Eur Respir J. 2007; 29 (6): 1127-1137. DOI: https://doi.org/10.1183/09031936.00147806
Perry CM, Brogden RN. Cefuroxime Axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996; 52 (1): 125-156. DOI: https://doi.org/10.2165/00003495-199652010-00009
Destache CJ, Dewan N, O’Donohue WJ, Campbell JC, Anqelillo VA. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemoth. 1999; 43: 107-113. DOI: https://doi.org/10.1093/jac/43.suppl_1.107
Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2004; 39 (7): 987-989.
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
